Preoperative chemoradiotherapy with capecitabine and triweekly oxaliplatin versus capecitabine monotherapy for locally advanced rectal cancer: a propensity-score matched study.

ABSTRACT:

Background

Distant metastasis has been the main failure pattern for locoregionally advanced rectal cancer (LARC) patients, and intensified neoadjuvant chemotherapy has become a popular research topic. The present study aimed to compare the survival outcomes, acute toxicities and surgical complications in LARC patients who received preoperative chemoradiotherapy with triweekly oxaliplatin and capecitabine (triweekly XELOX) or capecitabine.

Methods

Between 2007 and 2017, patients with clinically staged II-III rectal cancer who were treated with preoperative chemoradiotherapy using either triweekly XELOX (oxaliplatin 130 mg/m² plus capecitabine 825 mg/m²) or capecitabine were included. Variables potentially influencing chemotherapy treatment selection were

SUBMITTER: Li A 

PROVIDER: S-EPMC9295262 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature